News for Outlook Therapeutics, Inc. (OTLK)

In recent developments, Ascendiant Capital's analyst Edward Woo has made updates to his recommendation for Outlook Therapeutics (OTLK). According to the latest

Outlook Therapeutics (OTLK) has made LYTENAVA available commercially in both Germany and the UK, targeting the treatment of wet age-related macular degeneration

LYTENAVAâ„¢ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK)

Stock News● Microsoft (MSFT) has successfully concluded its legal battle with the Federal Trade Commission (FTC) over its $68.7 billion acquisition of Activis

Outlook Therapeutics (OTLK) has appointed BTIG as the exclusive book-running manager for its latest offering. This strategic decision underscores the company's

Outlook Therapeutics has initiated a significant public offering to bolster company finances. Analysts maintain a bullish outlook with an average target

Singapore-based INNEOVA Holdings Limited (INEO) is up over 51 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK), a biopharmaceutical company focused on enhancing the standard of care for b

Outlook Therapeutics (OTLK) announces a $13 million public offering of common stock and warrants. The offering includes 9,285,714 common shares priced a

**media[635165]**

LYTENAVAâ„¢ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act

Outlook Therapeutics (OTLK) is on course to establish itself as a commercial-stage entity by 2025, with plans to introduce LYTENAVA as a treatment for wet age-r

**media[589211]**

Overview of the Recent Transaction On January 17, 2025, SPHERA FUNDS MANAGEMENT LTD. (Trades, Portfolio) made a strategic move by acquiring 1,714,284 shares of

ISELIN, N.J., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. ( OTLK), a biopharmaceutical company that achieved regulatory approval in the Europ

**media[553399]**

**media[544681]**

On December 31, 2024, GREAT POINT PARTNERS LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 926,972 shares of Outlook Thera

Outlook Therapeutics (OTLK) reports Q1 GAAP EPS of $0.72. Key updates include $17.8M warrant proceeds in Jan '25 and $5.7M cash reserves as of Dec '24.